Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis.
Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis.
复制标题
高剂量马法兰和自体干细胞移植的串联循环可提高 AL 淀粉样变性的缓解率。
DOI：
10.1038/sj.bmt.1705746
复制
发表时间：
2007
影响因子：
4.8
通讯作者：
Seldin,DC
中科院分区：
文献类型：
--
作者：
Sanchorawala,V;Wright,DG;Quillen,K;Finn,KT;Dember,LM;Berk,JL;Doros,G;Fisher,C;Skinner,M;Seldin,DC
Clinical outcomes of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation (HDM/SCT) are tightly linked to the achievement of a hematologic complete response (HCR). We conducted a prospective trial to determine whether a second cycle of HDM/SCT could induce HCR in patients in whom the plasma cell dyscrasia persisted following initial treatment with HDM/SCT. Sixty-two patients were enrolled. Nine patients (15%) were removed from the protocol. Of the 53 patients continuing in this study, four died within 100 days of treatment (8%), and 27 (55%) achieved an HCR at 6 months after the first cycle of HDM/SCT. Of the 22 patients who did not achieve an HCR after initial treatment, 17 received a second HDM/SCT, 1 died within 100 days of treatment (6%), while 5 (31%) achieved an HCR. Thus, the HCR rate was 67%(32/48) for surviving patients on study, 60%(32/53) for all patients who received initial cycle of HDM/SCT, and 56%(35/62) by intention-to-treat. The median survival for all patients enrolled on the trial has not yet been reached. Thus, tandem cycles of HDM/SCT can increase the proportion of patients who achieve an HCR.
